Adaptimmune Therapeutics PLC
Develops novel T-cell therapies to treat solid tumors by engineering a patient's own immune cells.
ADAP | NDAQ
Overview
Corporate Details
- ISIN(s):
- US00653A1079
- LEI:
- Country:
- United States of America
- Address:
- 60 JUBILEE AVENUE, 0 ABINGDON, OXFORDSHIRE
- Website:
- https://www.adaptimmune.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company focused on developing novel cell therapies for cancer patients. The company specializes in treating challenging solid tumors through its proprietary T-cell therapy platform, which engineers a patient's own cells to identify and combat cancer. This personalized approach aims to harness the patient's immune system to provide transformative treatments. Adaptimmune maintains a robust pipeline of immunotherapy products to advance cancer care.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Adaptimmune Therapeutics PLC filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Adaptimmune Therapeutics PLC
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Adaptimmune Therapeutics PLC via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
